754 related articles for article (PubMed ID: 26363006)
1. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
2. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.
Hsu YL; Hung JY; Chiang SY; Jian SF; Wu CY; Lin YS; Tsai YM; Chou SH; Tsai MJ; Kuo PL
Oncotarget; 2016 May; 7(19):27584-98. PubMed ID: 27050278
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.
Rogers TJ; Christenson JL; Greene LI; O'Neill KI; Williams MM; Gordon MA; Nemkov T; D'Alessandro A; Degala GD; Shin J; Tan AC; Cittelly DM; Lambert JR; Richer JK
Mol Cancer Res; 2019 Jan; 17(1):30-41. PubMed ID: 30213797
[TBL] [Abstract][Full Text] [Related]
6. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
[TBL] [Abstract][Full Text] [Related]
7. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
8. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
[TBL] [Abstract][Full Text] [Related]
9. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
10. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
11. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
[TBL] [Abstract][Full Text] [Related]
12. Stemness and immune evasion conferred by the TDO2-AHR pathway are associated with liver metastasis of colon cancer.
Miyazaki T; Chung S; Sakai H; Ohata H; Obata Y; Shiokawa D; Mizoguchi Y; Kubo T; Ichikawa H; Taniguchi H; Aoki K; Soga T; Nakagama H; Okamoto K
Cancer Sci; 2022 Jan; 113(1):170-181. PubMed ID: 34714577
[TBL] [Abstract][Full Text] [Related]
13. EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway.
Mutz CN; Schwentner R; Kauer MO; Katschnig AM; Kromp F; Aryee DN; Erhardt S; Goiny M; Alonso J; Fuchs D; Kovar H
FEBS Lett; 2016 Jul; 590(14):2063-75. PubMed ID: 27282934
[TBL] [Abstract][Full Text] [Related]
14. The Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 Drives Anoikis Resistance and the Metastasis of Triple Negative Breast Cancer.
Johnson RM; Vu NT; Griffin BP; Gentry AE; Archer KJ; Chalfant CE; Park MA
J Biol Chem; 2015 Oct; 290(42):25717-27. PubMed ID: 26304115
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer.
Gu X; Han S; Cui M; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C
Ann N Y Acad Sci; 2019 Jul; 1448(1):5-18. PubMed ID: 30900271
[TBL] [Abstract][Full Text] [Related]
16. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis.
Huang YT; Lan Q; Lorusso G; Duffey N; Rüegg C
Oncotarget; 2017 Feb; 8(6):9200-9215. PubMed ID: 27911269
[TBL] [Abstract][Full Text] [Related]
17. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
Wang PS; Chou CH; Lin CH; Yao YC; Cheng HC; Li HY; Chuang YC; Yang CN; Ger LP; Chen YC; Lin FC; Shen TL; Hsiao M; Lu PJ
Oncogene; 2018 Aug; 37(34):4662-4678. PubMed ID: 29755127
[TBL] [Abstract][Full Text] [Related]
18. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
Kim JY; Lee N; Kim YJ; Cho Y; An H; Oh E; Cho TM; Sung D; Seo JH
Cancer Lett; 2017 Feb; 386():151-160. PubMed ID: 27894956
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
Guastella AR; Michelhaugh SK; Klinger NV; Fadel HA; Kiousis S; Ali-Fehmi R; Kupsky WJ; Juhász C; Mittal S
J Neurooncol; 2018 Sep; 139(2):239-249. PubMed ID: 29667084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
